Price
No data yet.
Social Signal Score
Analyst Ratings
14 analystsRevenue
$102.22M+1316.75%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Bahija Jallal
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 524
- Beta
- 0.81
- Country
- GB
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 1.13
Financials
Revenue
$102.22M+1316.7%Net Income
$-14.22MEBITDA
$-9.90MFree Cash Flow
$17.74MEPS (diluted)
$-0.28Shares Outstanding (diluted)
51.56M-75.9%Operating Expenses
$115.16MCash & Debt
$901.30MRevenue by Segment (annual)
$400.02MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $400.02M | $-35.51M | $-0.71 |
| 2024 | $310.48M | $-51.09M | $-1.02 |
| 2023 | $197.39M | $-43.75M | $-0.89 |
| 2022 | $144.23M | $-43.46M | $-0.95 |
| 2021 | $27.04M | $-133.45M | $-3.13 |
| 2020 | $30.11M | $-74.09M | $-2.33 |
| 2019 | $25.67M | $-103.93M | $-3.81 |
| 2018 | $23.65M | $-71.63M | $-2.62 |
| 2017 | $14.45M | $-49.57M | $-20.16 |
| 2016 | $16.46M | $-23.13M | $-9.45 |
| 2015 | $11.46M | $13.45M | $0.00 |
| 2014 | $6.38M | $-5.59M | $-2.53 |
| 2013 | $2.04M | $-3.69M | $0.00 |
Valuation
IMCRhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-28.57%Social Signal Score
Mentions (12)
- Newsglobenewswire.com·13d ago·Neutral
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 09 November 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced management will participate at the following conferences in November.
View source ↗ - Newsglobenewswire.com·16d ago·Neutral
Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma In 17 first-line patients treated with the combination, the estimated two-year overall survival (OS) rate was 70% - Median OS was not reached at a median follow-up of 29 months and 10 patients remained on study
View source ↗ - Newsglobenewswire.com·16d ago·Neutral
Immunocore reports third quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $102.2 million in Q3 2026 and net revenues of $324.8 million for the first nine months of 2026, representing 10% year-over-year growth year to date
View source ↗ - Newsglobenewswire.com·24d ago·Neutral
Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK ® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting
View source ↗ - Newsglobenewswire.com·38d ago·Neutral
…chanism of action recently published in Science Advances (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 15 October 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that the first patient with type 1 diabetes (T1D) has been dosed in t…
View source ↗ - Newsseekingalpha.com·68d ago·Positive
Immunocore Holdings plc (IMCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Immunocore Holdings plc (IMCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·69d ago·Neutral
…rall survival data expected as early as end of 2026 (OXFORDSHIRE, England & CONSHOHOCKEN, PA & ROCKVILLE, MD, US, 14 September 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced the achievement of target patient enrollment (540 patients) in the TE…
View source ↗ - Newsglobenewswire.com·82d ago·Neutral
… Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 1 September 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced management will participate at the following conferences in September…
View source ↗ - Newszacks.com·89d ago·Positive
Will Kimmtrak Continue to Aid IMCR's Growth Through the Rest of 2026? Strong demand for Kimmtrak is fueling Immunocore's growth, while potential label expansion and late-2026 data could add further upside.
View source ↗ - Newszacks.com·104d ago·Neutral
IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum Immunocore's 3-month gain reflects Kimmtrak growth and pipeline progress, but valuation and mixed signals temper the momentum case.
View source ↗ - Newszacks.com·104d ago·Positive
Is IMCR Worth Buying as Kimmtrak Growth Meets a Premium Valuation? Immunocore's Kimmtrak growth and late-stage catalysts strengthen its case, but a premium valuation and single-product risk raise the stakes.
View source ↗ - Newszacks.com·104d ago·Neutral
IMCR Q2 Revenues Climb 18.3% as Kimmtrak Demand Helps Offset EPS Miss Immunocore's Q2 revenue beat reflects strong Kimmtrak demand, but an EPS miss and distributor stocking headwind cloud the near-term outlook.
View source ↗
Earnings
Wed, Feb 24(in 3 months)
Consensus estimate $-0.23 per share
Typical surprise +4.8% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Nov 6$-0.28 vs $-0.12miss
- Thu, Aug 6$-0.02 vs $-0.01miss
- Wed, May 6$0.25 vs $-0.26beat
- Wed, Feb 25$-0.60 vs $-0.28miss
- Thu, Nov 6$0.02 vs $-0.30beat
- Thu, Aug 7$-0.20 vs $-0.21beat
Estimates and results for IMCR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IMCR officers and directors.
- Bought
- $24.0m
- Sold
- $10.7m
4 trades
18 trades
- Jallal Bahijasold
- Goll Johnsold
- St Leger Tina Ambersold
- Berman David Msold
- Berman David Msold
- Berman David Msold
- Berman David Msold
- Berman David Msold
77 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in IMCR.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
